Deramciclane

DB06512InvestigationalSmall molecule

Deramciclane (EGIS-3886) is used for the treatment of a number of anxiety disorders. Deramciclane differs from other anti anxiety medications in that it is not a benzodiazepine and so has... It antagonizes 5-HT2A receptors, agonizes 5-HT2C receptors, and functions as a GABA reuptake inhibitor.

Mechanism: Deramciclane is a new putative non-benzodiazepine-type anxiolytic compound. It is a selective serotonin 5-HT(2A) and 5-HT(2C) receptor antagonist and has also inverse agonist properties.
Curator reviewed
Primary indication: Investigated for use/treatment in anxiety disorders.Curator reviewed
Formula / weight: C₂₀H₃₁NO · 301.474 g/mol (avg)
Code names: EGIS-3886 · EGYT-3886

Resolves to

Compound

UNIIO5KFK61E74CAS120444-71-5ChEMBLCHEMBL2104698PubChem119590

Structure

InChIKeyQOBGWWQAMAPULA-RLLQIKCJSA-NSMILES[H][C@]12CC[C@](C)(C1(C)C)[C@@](C2)(OCCN(C)C)C1=CC=CC=C1

Targets

P28223HTR2AP28335HTR2C

What you can answer from here — as of March 12, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

961Drug interactionsStructured to mechanism, not free text

1Clinical trialPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Deramciclane, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account